You are hereRecent Publications of Members of the Boston Ithaca Islet Club / The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome

The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome


By JPGRAY - Posted on 24 February 2009

TitleThe role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome
Publication TypeJournal Article
Year of Publication2007
AuthorsPetersen KF, Dufour S, Savage DB, Bilz S, Solomon G, Yonemitsu S, Cline GW, Befroy D, Zemany L, Kahn BB, Papademetris X, Rothman DL, Shulman GI
JournalProc Natl Acad Sci U S A
Volume104
Issue31
Pagination12587-94
Date PublishedJul 31
Publication Languageeng
ISBN Number0027-8424 (Print)
Accession Number17640906
Key WordsMuscle, Skeletal/*metabolism, Insulin Resistance/*physiology, Humans, Glycogen/metabolism, Fasting, Metabolic Syndrome X/epidemiology/*metabolism, Magnetic Resonance Imaging, Hormones/blood, Cytokines/blood
Abstract

We examined the hypothesis that insulin resistance in skeletal muscle promotes the development of atherogenic dyslipidemia, associated with the metabolic syndrome, by altering the distribution pattern of postprandial energy storage. Following ingestion of two high carbohydrate mixed meals, net muscle glycogen synthesis was reduced by approximately 60% in young, lean, insulin-resistant subjects compared with a similar cohort of age-weight-body mass index-activity-matched, insulin-sensitive, control subjects. In contrast, hepatic de novo lipogenesis and hepatic triglyceride synthesis were both increased by >2-fold in the insulin-resistant subjects. These changes were associated with a 60% increase in plasma triglyceride concentrations and an approximately 20% reduction in plasma high-density lipoprotein concentrations but no differences in plasma concentrations of TNF-alpha, IL-6, adiponectin, resistin, retinol binding protein-4, or intraabdominal fat volume. These data demonstrate that insulin resistance in skeletal muscle, due to decreased muscle glycogen synthesis, can promote atherogenic dyslipidemia by changing the pattern of ingested carbohydrate away from skeletal muscle glycogen synthesis into hepatic de novo lipogenesis, resulting in an increase in plasma triglyceride concentrations and a reduction in plasma high-density lipoprotein concentrations. Furthermore, insulin resistance in these subjects was independent of changes in the plasma concentrations of TNF-alpha, IL-6, high-molecular-weight adiponectin, resistin, retinol binding protein-4, or intraabdominal obesity, suggesting that these factors do not play a primary role in causing insulin resistance in the early stages of the metabolic syndrome.

Notes

M01 RR 00125/RR/NCRR NIH HHS/United StatesP01 DK 068229/DK/NIDDK NIH HHS/United StatesP30 DK 45735/DK/NIDDK NIH HHS/United StatesR01 AG 23686/AG/NIA NIH HHS/United StatesR01 DK 43051/DK/NIDDK NIH HHS/United StatesR01 EB 006494/EB/NIBIB NIH HHS/United StatesJournal ArticleResearch Support, N.I.H., ExtramuralResearch Support, Non-U.S. Gov'tUnited States

URLhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17640906
Citation Key480
Export

Signup to receive email notifications of upcoming events

To signup to receive email notifications of upcoming BIIC events, fill out the information here.